Stages I-III Pancreatic Cancer


Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for... Continue Reading

Pancreatic Cancer Cells Find Unique Fuel Sources to Keep from Starving (August 17, 2016)

Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice... Continue Reading

MabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in a Phase I Clinical Trial for the Treatment for Pancreatic Cancer (January 11, 2016)

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug development company, announces that it has received notice from the U.S. Food and Drug Administration (FDA) authorizing the initiation... Continue Reading

“Boosted” Radiation Dose May Make Some Pancreatic Cancers Resectable (June 24, 2015)

Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically... Continue Reading

Jakafi Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation (June 2, 2014)

In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that treatment with Jakafi® (ruxolitinib) plus capecitabine improved overall survival... Continue Reading

Sutent Approved for Pancreatic Neuroendocrine Tumors (PNET) (June 2, 2011)

The US Food and Drug Administration has approved the targeted drug Sutent® (sunitinib) for the treatment pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are an uncommon type... Continue Reading

Afinitor Approved for Pancreatic Neuroendocrine Tumors (May 10, 2011)

The US Food and Drug Administration has approved Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are a relatively uncommon... Continue Reading

New Approach to Immune Therapy Shows Promise against Pancreatic Cancer (April 1, 2011)

An investigational type of immune therapy that attacks the tissue around a tumor has shown promise in a small study of patients with advanced pancreatic cancer. These results were published in the journal... Continue Reading

Addition of Axitinib Fails to Improve Pancreatic Cancer Outcomes (February 23, 2011)

Among patients with advanced pancreatic cancer, treatment with a combination of Gemzar® (gemcitabine) and the investigational drug axitinib did not result in better outcomes than treatment with Gemzar... Continue Reading

Gemzar Versus 5-FU for Adjuvant Treatment of Pancreatic Cancer (September 21, 2010)

A large randomized study demonstrated no significant improvement in survival with Gemzar® (gemcitabine) versus 5-fluorouracil (5-FU) for the adjuvant (post-surgery) treatment of pancreatic cancer. These... Continue Reading

Novel Chemotherapy Regimen for Locally Advanced Pancreatic Cancer (March 30, 2010)

A novel chemotherapy regimen followed by radiation appears to be safe and effective for patients with locally advanced pancreatic cancer, resulting in an overall survival of 66%. These study results were... Continue Reading

November Is National Pancreatic Cancer Awareness Month (November 5, 2009)

As the month of November brings pancreatic cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options,... Continue Reading

Chemotherapy Improves Pancreatic Cancer Survival (September 10, 2009)

Among patients with inoperable pancreatic cancer, Gemzar® (gemcitabine)-based chemotherapy results in longer survival and better quality of life than an alternative treatment regimen consisting of enzyme... Continue Reading

Pancreatic Cancer Care Is Inconsistent (July 21, 2009)

The quality of care for pancreatic cancer varies considerably among hospitals in the United States, according to the results of a study published in the Journal of the National Cancer Institute.[1] Pancreatic... Continue Reading

Neoadjuvant Radiation Improves Survival in Pancreatic Cancer (December 5, 2008)

Neoadjuvant Radiation Improves Survival in Pancreatic Cancer Preoperative radiation nearly doubles the survival rate for patients with operable pancreatic cancer, according to the results of a study published... Continue Reading

EndoTAG™-1 Shows Promise in Treatment of Pancreatic Cancer (September 17, 2008)

According to the results of a Phase II clinical trial, the addition of the investigational drug EndoTAG™-1 to chemotherapy with Gemzar® (gemcitabine) may improve survival among patients with inoperable... Continue Reading

Removal of More Lymph Nodes May Improve Survival in Gastric and Pancreatic Cancers (July 23, 2008)

Removal of More Lymph Nodes May Improve Survival in Gastric and Pancreatic Cancers Researchers recommend that at least 15 lymph nodes be removed and examined in patients with early gastric or pancreatic... Continue Reading

Gemzar® Improves Survival with Early Pancreatic Cancer (June 10, 2008)

Gemzar® Improves Survival with Early Pancreatic Cancer Adjuvant (post-surgery) chemotherapy with Gemzar® (gemcitabine) significantly improves disease-free and overall survival among patients with early... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS